Sarpogrelate Hydrochloride

盐酸沙格雷酯

Report date: 2023/02/21 16:22:59
NME

Base Information

Drug NameSarpogrelate Hydrochloride
Drug Alias Name沙格雷酯AnplagLS-118LS-187MCI-9042
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin (5-HT) receptor modulators
TargetsSerotonin (5-HT) receptor
Therapy Area/IndicationsThromboembolismPeripheral Arterial DiseaseArterial Occlusive Diseases +[4
Global Approved IndicationsThromboembolismArterial Occlusive Diseases
Approved Indications in ChinaArterial Occlusive Diseases
Original Approved Country/TerritoryJapan
Original Approved Date1993/07/02
Country/TerritorySouth KoreaMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMitsubishi Tanabe Pharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesMitsubishi Tanabe Pharma
Active IndicationsThromboembolismArterial Occlusive Diseases
Inactive IndicationsPeripheral Arterial DiseaseCerebral Infarction

Other Information

ATC CodeB01A
Related LinksWikipediaKEGG